Theriva Biologics Valuation

Is SFY0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SFY0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SFY0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SFY0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SFY0?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SFY0. This is calculated by dividing SFY0's market cap by their current preferred multiple.
What is SFY0's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$5.93m

SFY0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SFY0's PB Ratio compare to its peers?

The above table shows the PB ratio for SFY0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	11.7x
CNW co.don	1x	n/a	€6.5m
MDG1 Medigene	1.5x	-4.1%	€29.9m
T5O bioXXmed	1.5x	n/a	€703.8k
VSC 4SC	42.7x	n/a	€46.8m
SFY0 Theriva Biologics	0.2x	-4.5%	€5.9m

Price-To-Book vs Peers: SFY0 is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (15.2x).

Price to Earnings Ratio vs Industry

How does SFY0's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.1%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: SFY0 is good value based on its Price-To-Book Ratio (0.2x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is SFY0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SFY0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SFY0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SFY0 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€2.42	€89.88 +3,614.0%	75.0%	€157.29	€22.47	n/a	2
May ’25	€9.30	€103.75 +1,015.6%	55.6%	€161.39	€46.11	n/a	2
Apr ’25	€10.15	€103.75 +922.1%	55.6%	€161.39	€46.11	n/a	2
Mar ’25	€10.25	€103.75 +912.2%	55.6%	€161.39	€46.11	n/a	2
Feb ’25	€11.10	€103.75 +834.7%	55.6%	€161.39	€46.11	n/a	2
Jan ’25	€9.50	€103.75 +992.1%	55.6%	€161.39	€46.11	n/a	2
Dec ’24	€13.50	€103.75 +668.5%	55.6%	€161.39	€46.11	n/a	2
Nov ’24	€10.25	€102.65 +901.4%	55.6%	€159.67	€45.62	n/a	2
Oct ’24	€11.35	€102.65 +804.4%	55.6%	€159.67	€45.62	n/a	2
Sep ’24	€11.60	€102.65 +784.9%	55.6%	€159.67	€45.62	€2.42	2
Aug ’24	€15.00	€140.62 +837.5%	27.3%	€178.97	€102.27	€4.50	2
Jul ’24	€20.75	€140.62 +577.7%	27.3%	€178.97	€102.27	€5.00	2
Jun ’24	€15.88	€140.62 +785.8%	27.3%	€178.97	€102.27	€5.68	2
May ’24	€14.75	€140.62 +853.4%	27.3%	€178.97	€102.27	€9.30	2
Apr ’24	€15.88	€140.62 +785.8%	27.3%	€178.97	€102.27	€10.15	2
Mar ’24	€20.88	€140.62 +573.6%	27.3%	€178.97	€102.27	€10.25	2
Feb ’24	€20.50	€140.62 +586.0%	27.3%	€178.97	€102.27	€11.10	2
Jan ’24	€10.30	€140.62 +1,265.3%	27.3%	€178.97	€102.27	€9.50	2
Dec ’23	€17.00	€140.62 +727.2%	27.3%	€178.97	€102.27	€13.50	2
Nov ’23	€19.00	€140.62 +640.1%	27.3%	€178.97	€102.27	€10.25	2
Oct ’23	€26.50	€146.12 +451.4%	33.3%	€194.82	€97.41	€11.35	2
Sep ’23	€37.00	€146.12 +294.9%	33.3%	€194.82	€97.41	€11.60	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.